Myelodysplastic Syndrome Treatment Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis
Myelodysplastic syndrome is a group of disorders is associated with the disrupted blood cells production. Some myelodysplastic syndromes have no cause but others are casued by exposure to cancer treatment, such as such as chemotherapy and radiation, exposure to toxic chemical, such as benzene. Symptoms of Myelodysplastic syndrome include shortness of breath, fatigue, easy bruising and paleness. It may progress to leukemia. The symptoms are manageable by Transfusions and medication.
MARKET SCOPE
The "Global Myelodysplastic Syndrome Treatment Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Myelodysplastic Syndrome Treatment market with detailed market segmentation by administration, drug, and distribution channel. The report provides key statistics on the market status of the leading Myelodysplastic Syndrome Treatment market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on administration the market is segmented as, oral and intravenous.
- Based on the drug the market is segmented as, lenalidomide, decitabine, azacitidine, and phase 3 drugs.
- Based on the distribution channel the market is segmented as, hospital pharmacies, retail pharmacies, and online sales.
MARKET DYNAMICS
Drivers:
- Rising prevalence of Myelodysplastic Syndrome.
- Increased procedures of chemotherapy, radiotherapy, and chemical exposures.
- Increased use of toxic chemical in medical procedures, pharmaceutical and chemical companies.
Restraints:
- Whereas, the high cost of treatment for myelodysplastic syndrome is expected to restrain the market growth during the forecast period.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 concerning five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South and Central America. The Myelodysplastic Syndrome Treatment market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both the demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South and Central America after evaluating political, economic, social, and technological factors affecting the Myelodysplastic Syndrome Treatment market in these regions.
IMPACT OF COVID-19 ON MYELODYSPLASTIC SYNDROME TREATMENT MARKET
COVID-19 first began in Wuhan (China) in December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in the global market. Few companies have already announced possible delays in product deliveries and slumps in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 concerning five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South and Central America. The Myelodysplastic Syndrome Treatment market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both the demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South and Central America after evaluating political, economic, social, and technological factors affecting the Myelodysplastic Syndrome Treatment market in these regions.
IMPACT OF COVID-19 ON MYELODYSPLASTIC SYNDROME TREATMENT MARKET
COVID-19 first began in Wuhan (China) in December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in the global market. Few companies have already announced possible delays in product deliveries and slumps in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
MARKET PLAYERS
The report covers key developments in the Myelodysplastic Syndrome Treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals, and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnerships & collaborations. These activities have paved the way for the expansion of business and the customer base of market players. The market payers from the Myelodysplastic Syndrome Treatment market are anticipated to have lucrative growth opportunities in the future with the rising demand for Myelodysplastic Syndrome Treatment in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Myelodysplastic Syndrome Treatment market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- SUN PHARMACEUTICAL INDUSTRIES LIMITED
- DR. REDDY'S LABORATORIES LTD.
- MYLAN NV
- CIPLA LIMITED
- CELGENE CORPORATION
- OTSUKA PHARMACEUTICAL CO., LTD.
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- ONCONOVA THERAPEUTICS INC.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Myelodysplastic Syndrome Treatment Market - By Administration
1.3.2 Myelodysplastic Syndrome Treatment Market - By Drug
1.3.3 Myelodysplastic Syndrome Treatment Market - By Distribution Channel
1.3.4 Myelodysplastic Syndrome Treatment Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. MYELODYSPLASTIC SYNDROME TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. MYELODYSPLASTIC SYNDROME TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. MYELODYSPLASTIC SYNDROME TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. MYELODYSPLASTIC SYNDROME TREATMENT - GLOBAL MARKET OVERVIEW
6.2. MYELODYSPLASTIC SYNDROME TREATMENT - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. MYELODYSPLASTIC SYNDROME TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - ADMINISTRATION
7.1. OVERVIEW
7.2. ADMINISTRATION MARKET FORECASTS AND ANALYSIS
7.3. ORAL
7.3.1. Overview
7.3.2. Oral Market Forecast and Analysis
7.4. INTRAVENOUS
7.4.1. Overview
7.4.2. Intravenous Market Forecast and Analysis
8. MYELODYSPLASTIC SYNDROME TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DRUG
8.1. OVERVIEW
8.2. DRUG MARKET FORECASTS AND ANALYSIS
8.3. LENALIDOMIDE
8.3.1. Overview
8.3.2. Lenalidomide Market Forecast and Analysis
8.4. DECITABINE
8.4.1. Overview
8.4.2. Decitabine Market Forecast and Analysis
8.5. AZACITIDINE
8.5.1. Overview
8.5.2. Azacitidine Market Forecast and Analysis
8.6. PHASE 3 DRUGS
8.6.1. Overview
8.6.2. Phase 3 Drugs Market Forecast and Analysis
9. MYELODYSPLASTIC SYNDROME TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACIES
9.3.1. Overview
9.3.2. Hospital Pharmacies Market Forecast and Analysis
9.4. RETAIL PHARMACIES
9.4.1. Overview
9.4.2. Retail Pharmacies Market Forecast and Analysis
9.5. ONLINE PHARMACIES
9.5.1. Overview
9.5.2. Online Pharmacies Market Forecast and Analysis
10. MYELODYSPLASTIC SYNDROME TREATMENT MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Myelodysplastic Syndrome Treatment Market Overview
10.1.2 North America Myelodysplastic Syndrome Treatment Market Forecasts and Analysis
10.1.3 North America Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Administration
10.1.4 North America Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Drug
10.1.5 North America Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Countries
10.1.6.1 United States Myelodysplastic Syndrome Treatment Market
10.1.6.1.1 United States Myelodysplastic Syndrome Treatment Market by Administration
10.1.6.1.2 United States Myelodysplastic Syndrome Treatment Market by Drug
10.1.6.1.3 United States Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.1.6.2 Canada Myelodysplastic Syndrome Treatment Market
10.1.6.2.1 Canada Myelodysplastic Syndrome Treatment Market by Administration
10.1.6.2.2 Canada Myelodysplastic Syndrome Treatment Market by Drug
10.1.6.2.3 Canada Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.1.6.3 Mexico Myelodysplastic Syndrome Treatment Market
10.1.6.3.1 Mexico Myelodysplastic Syndrome Treatment Market by Administration
10.1.6.3.2 Mexico Myelodysplastic Syndrome Treatment Market by Drug
10.1.6.3.3 Mexico Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Myelodysplastic Syndrome Treatment Market Overview
10.2.2 Europe Myelodysplastic Syndrome Treatment Market Forecasts and Analysis
10.2.3 Europe Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Administration
10.2.4 Europe Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Drug
10.2.5 Europe Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Myelodysplastic Syndrome Treatment Market
10.2.6.1.1 Germany Myelodysplastic Syndrome Treatment Market by Administration
10.2.6.1.2 Germany Myelodysplastic Syndrome Treatment Market by Drug
10.2.6.1.3 Germany Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.2.6.2 France Myelodysplastic Syndrome Treatment Market
10.2.6.2.1 France Myelodysplastic Syndrome Treatment Market by Administration
10.2.6.2.2 France Myelodysplastic Syndrome Treatment Market by Drug
10.2.6.2.3 France Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.2.6.3 Italy Myelodysplastic Syndrome Treatment Market
10.2.6.3.1 Italy Myelodysplastic Syndrome Treatment Market by Administration
10.2.6.3.2 Italy Myelodysplastic Syndrome Treatment Market by Drug
10.2.6.3.3 Italy Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.2.6.4 Spain Myelodysplastic Syndrome Treatment Market
10.2.6.4.1 Spain Myelodysplastic Syndrome Treatment Market by Administration
10.2.6.4.2 Spain Myelodysplastic Syndrome Treatment Market by Drug
10.2.6.4.3 Spain Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.2.6.5 United Kingdom Myelodysplastic Syndrome Treatment Market
10.2.6.5.1 United Kingdom Myelodysplastic Syndrome Treatment Market by Administration
10.2.6.5.2 United Kingdom Myelodysplastic Syndrome Treatment Market by Drug
10.2.6.5.3 United Kingdom Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.2.6.6 Rest of Europe Myelodysplastic Syndrome Treatment Market
10.2.6.6.1 Rest of Europe Myelodysplastic Syndrome Treatment Market by Administration
10.2.6.6.2 Rest of Europe Myelodysplastic Syndrome Treatment Market by Drug
10.2.6.6.3 Rest of Europe Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Myelodysplastic Syndrome Treatment Market Overview
10.3.2 Asia-Pacific Myelodysplastic Syndrome Treatment Market Forecasts and Analysis
10.3.3 Asia-Pacific Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Administration
10.3.4 Asia-Pacific Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Drug
10.3.5 Asia-Pacific Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Myelodysplastic Syndrome Treatment Market
10.3.6.1.1 Australia Myelodysplastic Syndrome Treatment Market by Administration
10.3.6.1.2 Australia Myelodysplastic Syndrome Treatment Market by Drug
10.3.6.1.3 Australia Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.3.6.2 China Myelodysplastic Syndrome Treatment Market
10.3.6.2.1 China Myelodysplastic Syndrome Treatment Market by Administration
10.3.6.2.2 China Myelodysplastic Syndrome Treatment Market by Drug
10.3.6.2.3 China Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.3.6.3 India Myelodysplastic Syndrome Treatment Market
10.3.6.3.1 India Myelodysplastic Syndrome Treatment Market by Administration
10.3.6.3.2 India Myelodysplastic Syndrome Treatment Market by Drug
10.3.6.3.3 India Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.3.6.4 Japan Myelodysplastic Syndrome Treatment Market
10.3.6.4.1 Japan Myelodysplastic Syndrome Treatment Market by Administration
10.3.6.4.2 Japan Myelodysplastic Syndrome Treatment Market by Drug
10.3.6.4.3 Japan Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.3.6.5 South Korea Myelodysplastic Syndrome Treatment Market
10.3.6.5.1 South Korea Myelodysplastic Syndrome Treatment Market by Administration
10.3.6.5.2 South Korea Myelodysplastic Syndrome Treatment Market by Drug
10.3.6.5.3 South Korea Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.3.6.6 Rest of Asia-Pacific Myelodysplastic Syndrome Treatment Market
10.3.6.6.1 Rest of Asia-Pacific Myelodysplastic Syndrome Treatment Market by Administration
10.3.6.6.2 Rest of Asia-Pacific Myelodysplastic Syndrome Treatment Market by Drug
10.3.6.6.3 Rest of Asia-Pacific Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Myelodysplastic Syndrome Treatment Market Overview
10.4.2 Middle East and Africa Myelodysplastic Syndrome Treatment Market Forecasts and Analysis
10.4.3 Middle East and Africa Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Administration
10.4.4 Middle East and Africa Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Drug
10.4.5 Middle East and Africa Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Myelodysplastic Syndrome Treatment Market
10.4.6.1.1 South Africa Myelodysplastic Syndrome Treatment Market by Administration
10.4.6.1.2 South Africa Myelodysplastic Syndrome Treatment Market by Drug
10.4.6.1.3 South Africa Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.4.6.2 Saudi Arabia Myelodysplastic Syndrome Treatment Market
10.4.6.2.1 Saudi Arabia Myelodysplastic Syndrome Treatment Market by Administration
10.4.6.2.2 Saudi Arabia Myelodysplastic Syndrome Treatment Market by Drug
10.4.6.2.3 Saudi Arabia Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.4.6.3 U.A.E Myelodysplastic Syndrome Treatment Market
10.4.6.3.1 U.A.E Myelodysplastic Syndrome Treatment Market by Administration
10.4.6.3.2 U.A.E Myelodysplastic Syndrome Treatment Market by Drug
10.4.6.3.3 U.A.E Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Myelodysplastic Syndrome Treatment Market
10.4.6.4.1 Rest of Middle East and Africa Myelodysplastic Syndrome Treatment Market by Administration
10.4.6.4.2 Rest of Middle East and Africa Myelodysplastic Syndrome Treatment Market by Drug
10.4.6.4.3 Rest of Middle East and Africa Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Myelodysplastic Syndrome Treatment Market Overview
10.5.2 South and Central America Myelodysplastic Syndrome Treatment Market Forecasts and Analysis
10.5.3 South and Central America Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Administration
10.5.4 South and Central America Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Drug
10.5.5 South and Central America Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Myelodysplastic Syndrome Treatment Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Myelodysplastic Syndrome Treatment Market
10.5.6.1.1 Brazil Myelodysplastic Syndrome Treatment Market by Administration
10.5.6.1.2 Brazil Myelodysplastic Syndrome Treatment Market by Drug
10.5.6.1.3 Brazil Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.5.6.2 Argentina Myelodysplastic Syndrome Treatment Market
10.5.6.2.1 Argentina Myelodysplastic Syndrome Treatment Market by Administration
10.5.6.2.2 Argentina Myelodysplastic Syndrome Treatment Market by Drug
10.5.6.2.3 Argentina Myelodysplastic Syndrome Treatment Market by Distribution Channel
10.5.6.3 Rest of South and Central America Myelodysplastic Syndrome Treatment Market
10.5.6.3.1 Rest of South and Central America Myelodysplastic Syndrome Treatment Market by Administration
10.5.6.3.2 Rest of South and Central America Myelodysplastic Syndrome Treatment Market by Drug
10.5.6.3.3 Rest of South and Central America Myelodysplastic Syndrome Treatment Market by Distribution Channel
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. MYELODYSPLASTIC SYNDROME TREATMENT MARKET, KEY COMPANY PROFILES
12.1. SUN PHARMACEUTICAL INDUSTRIES LIMITED
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. DR. REDDY'S LABORATORIES LTD.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. MYLAN NV
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. CIPLA LIMITED
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. CELGENE CORPORATION
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. OTSUKA PHARMACEUTICAL CO., LTD.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. ONCONOVA THERAPEUTICS INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1.Sun Pharmaceutical Industries Limited
2.Dr. Reddy's Laboratories Ltd.
3.Mylan NV
4.Cipla Limited
5.Celgene Corporation
6.Otsuka Pharmaceutical Co., Ltd.
7.Teva Pharmaceutical Industries Ltd.
8.Onconova Therapeutics Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For